Navigation Links
DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
Date:9/10/2007

EL SEGUNDO, Calif., Sept. 10 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA) announced today that it has acquired 85% of the outstanding stock of HomeChoice Partners, Inc. for approximately $65 million in cash. HomeChoice, based in Norfolk, Virginia, provides a broad range of infusion therapy services to patients with acute or chronic conditions that can be treated at home or at an ambulatory infusion suite. HomeChoice has reported approximately $37 million in trailing twelve month revenue and currently serves over 2000 patients in Virginia, North Carolina, South Carolina and Georgia. The acquisition is expected to be EPS neutral in the first year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

The remaining 15% ownership interest will be retained by current HomeChoice senior management. This minority interest is subject to annual put and call options beginning 4 years from the date of closing.

"HomeChoice is a high quality company in a large and fragmented healthcare segment. It has an experienced management team that will fit well with DaVita's culture and our focus on outstanding clinical outcomes. We have modest initial growth plans, but as we learn the business we will evaluate the possibility for further investment in infusion services," said Kent Thiry, CEO of DaVita.

"HomeChoice is proud and excited to be part of a national healthcare company where the primary focus is to be the leader in patient outcomes. DaVita and HomeChoice are totally aligned in our goal to maintain that clinical leadership," said Mary Ann Cope, founder and President of HomeChoice.

This release contains forward-looking statements. Factors which could impact future results include the risk factors set forth in DaVita's SEC filings, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The forward-looking statements should be considered in light of these risks and uncertainties. DaVita undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DaVita Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ossur Acquires the U.S. Orthopaedics Company
2. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
3. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
4. Premier Army Hospital Acquires PET-CT Scanner
5. Wockhardt acquires Protinex, Farex brands from Netherland Co
6. Indoco Remedies Acquires La Nova Chem
7. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
8. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
9. Apollos Global Arm Acquires US-based Firm
10. ‘Obesity’ Acquires Permanent Resident Status in the US
11. Indias Wockhardt Acquires Irish Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: